1. Xience V® Update Building the Future on the Foundation of Angiographic and Clinical Superiority Chuck Simonton MD, FACC, FSCAI Chief Medical Officer, Abbott Vascular
CRT 2010 1

2. Charles A. Simonton, MD DISCLOSURES
Chief Medical Officer Abbott Vascular Santa Clara, CA

3. XIENCE V: Best-in-Class Components

4. XIENCE V: Thinnest Struts of Any DES1
CYPHER
TAXUS Liberté
ENDEAVOR
XIENCE V
Strut Thickness:
140 mm
Coating Thickness:
12.6 mm
Strut Thickness:
97 mm
Coating Thickness:
17.8 mm
Strut Thickness:
91 mm
Coating Thickness:
4.8 mm
Strut Thickness:
81 mm
Coating Thickness:
7.8 mm
NEED LIBERTE picture.
Total = um um um um
3.0 mm diameter stents, 500x magnification
1Manufacturer-reported strut thickness. Data on file at Abbott Vascular.

5. Investment in Clinical Programs: Worldwide DES Clinical Trials
NOTE: For trials that have completed enrollment, numbers are final enrollment. For trials that are planned or still enrolling, numbers are per protocol
XIENCE to be studied in
~29,000
patients
Pre-Approval
Post-Market
Trial Name
# of Enrolling Sites
# of Patients
Time Patients Followed
Trial Name
# of Enrolling Sites
# of Patients
Time Patients Followed
SPIRIT V
SPIRIT Women
XIENCE V USA 2
XIENCE V India
XIENCE V China
XIENCE V Japan
XIENCE V EXCEED
FAR XIENCE V 1
XERES 1
EXECUTIVE 1
112
100
250 19
TBD 83 58 24 30
3,025
2,050
~8,000
1,000
~2,450
~1,900
2,500
1,200
100
600
5 yrs
3 yrs
Acute
2 yrs
SPIRIT FIRST 1
SPIRIT II
SPIRIT III
SPIRIT III Japan
SPIRIT IV
SPIRIT Small Vessel
SPIRIT PRIME 9 28 65 12 58 50 75 60
300
1,002 88
3,690
150
500
5 yrs
1 European Study
2 XIENCE V USA will include a DAPT subset; 5-year patient follow-up on a subset; additional subsets have 33-month or 12-month follow-up
Note: This product is currently CE marked. Where CE marking is not the registration in force, this product may be in Abbott Vascular’s pipeline.
For trials that have completed enrollment, numbers are final enrollment. For trials that are planned or still enrolling, numbers are per protocol 6

6. SPIRIT III Trial Design & Demographics2 : 1
XIENCE V
(N = 669)
TAXUS
(Control = 333)
Up to two de novo lesions, maximum of one lesion per epicardial vessel
RVD: 2.5 – 3.75 mm
LL: 28 mm
N = 1,002
65 US sites
PI: Gregg Stone, MD
RCT: Prospective, single blind
Primary end point: In-segment Late Loss at 8M
Stent Size: 2.5 – 3.5 mm; Stent lengths: 8, 18, 28 mm
Angiographic and IVUS Follow-Up on 564 and 240 pts, respectively
Clinical follow-up at 30, 180, 270d and 1, 2, 3, 4 and 5 years
6 Months clopidogrel for all arms
SPIRIT III Trial Objective
To determine the safety and efficacy of the ML XIENCE V™ EECS System in patients with de novo native coronary artery lesions. SPIRIT III was the pivotal trial in the US for FDA approval.
XIENCE V
TAXUS
P-Value
Patients
669
332 NA
RVD (mm)*
2.77 ±0.5
2.76 ±0.5
Lesion Length (mm)*
14.7 ±5.6
14.7 ±5.7
Diabetics
29.6%
27.9%
0.60 7
Taxus Express2 was used as the control in SPIRIT III.
*SOURCE: Stone, Gregg, JAMA. Vol 299, No. 16 7

7. SPIRIT III 3-Year Major Adverse Cardiac Events
XIENCE V®
TAXUS®
3-year HR
2-year HR
0.57 [0.39, 0.83]
0.55 [0.37, 0.82]
p=0.003
1-year HR
p=0.003
0.56 [0.35, 0.90]
15.7%
13.1%
p=0.01
MACE (%)
∆6.6%
9.9%
∆5.6%
∆4.2%
9.1%
7.5%
XIENCE V: Delivers long term safety
The difference in MACE between XIENCE V and TAXUS continues to widen between 1, 2 and 3 years with a 43% reduction in MACE at 3 years
5.7%
Number at risk
XIENCE V®
669
652
643
628
612
598
597
591
581
576
574
572
569
TAXUS®
332
312
308
291
286
275
272
269
266
264
260
258
255
Months 8
Taxus Express2 was used as the control in SPIRIT III.
SOURCE: Gregg Stone SPIRIT III 3 Year Results TCT 2009 8

8. Taxus Express2 was used as the control in SPIRIT III.
SPIRIT III 3-Year Landmark Analysis Stent Thrombosis (ARC)
0.3% VLST (ARC Definite + Probable)
0% S.T. between years 2 & 3 in 669 pts
TAXUS
XIENCE V
2-year HR
0.32 [0.05, 1.93]
p=0.19
3-year HR
0.32 [0.05, 1.93]
p=0.19
1-year HR
1.48 [0.30, 7.31]
p=0.63
Stent Thrombosis (%)
0.15% per year---BMS like
1.0%
1.0%
Low 0.3% very late stent thrombosis rates (ARC Def/Prob) between 1 and 3 years; 0% stent thrombosis rate from 2 to 3 years in 669 patients
XIENCE V had a low 0.3% rate of stent thrombosis between 1 and 3 years, no new ST from years 2 to 3.
0.9%
∆0.7%
∆0.7%
∆-0.6%
0.3%
0.3%
0.3%
Months
Taxus Express2 was used as the control in SPIRIT III.
SOURCE: David Cox SPIRIT III 3 Year Results TCT 2009

9. SPIRIT IV XIENCE V TAXUS Randomized 2:1 XIENCE V:TAXUS Express2
***Clinical f/u only: 1, 6, 9 months and yearly for 1-5 years
***Pt. driven events not impacted by angiographic F/U
***Largest RCT to comparing two DES (↑ diabetic pop.)
100% monitoring: reflects high quality data arising from this trial
RVD ≥2.5 mm - ≤3.75 mm; Lesion length ≤28 mm
Max. 3 lesions with a maximum of 2 per epicardial vessel
Pre-rand: ASA ≥300 mg, clopidogrel ≥300 mg load unless on chronic Rx
3690 pts enrolled at 66 U.S. sites
Randomized 2:1 XIENCE V:TAXUS Express2
Stratified by diabetes and presence of complex lesions
Pre-dilatation mandatory
Everolimus-eluting
XIENCE V
Paclitaxel-eluting
TAXUS
SPIRIT IV Trial Design Key Messages
Largest RCT between two DES to have presented primary endpoint data
One of the largest subsets of patients with diabetes (n=1185 enrolled)
Clinically-driven primary and secondary endpoints – Patient driven events not impacted by angiographic follow-up
100% monitoring – Reflective of the quality of data arising from the trial
Aspirin ≥80 mg QD for 5 years; clopidogrel 75mg QD for at least 12 mos (if not at high risk for bleeding) 10
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009 10 10

10. Target lesion failure (%)
SPIRIT IV: Primary Endpoint (TLF) Early & Continuously Divergent Differences
HR [95%CI] = [0.46, 0.82]
XIENCE V
TAXUS
p=0.0008
TLF = cardiac death, target vessel MI, and ischemia-driven TLR
6.6%
Number Needed to Treat (NNT) to prevent one TLF Event = 37
Target lesion failure (%)
Δ 2.7%
TAXUS
3.9%
XIENCE V
XIENCE V delivers clinical superiority in the largest RCT between two DES to have presented primary endpoint data.
XIENCE V proved superior to TAXUS in the clinically-driven primary endpoint of target lesion failure (TLF)
(3.9% vs. 6.6%, p=0.0008)
Months
XIENCE V
2458
2390
2362
2323
2298
TAXUS
1229
1165
1137
1119
1104
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009

11. NNT (number needed to treat) to avoid 1 ST is only 125 Patients
SPIRIT IV 1 Year Stent Thrombosis: ARC Definite or Probable
XIENCE V
TAXUS
HR [95%CI] = 0.27 [0.11, 0.67]
p=0.003
NNT (number needed to treat) to avoid 1 ST is only 125 Patients
TAXUS
1.06%
Stent thrombosis (%)
≈73% ↓ in S.T. at 1 year
Δ 0.77%
XIENCE V
XIENCE V delivers long-term safety. 74% reduction in the risk of stent thrombosis (ARC def or prob) at 1 year SPIRIT IV (p=.004).
0.29%
Months
XIENCE V
2458
2426
2412
2388
2376
TAXUS
1229
1195
1184
1174
1166
SOURCE: Gregg Stone SPIRIT IV 1 Year Results TCT 2009

12. Chronic renal failure 3 %
COMPARE Trial Prospective, single-center RCT XIENCE V vs. TAXUS Liberté in 1800 Patients
AMI 25 %
Calcification 34 %
Multistenting 62 %
Ostial 19 %
Thrombus 24 %
CTO 4 %
NSTEMI 23 %
Multivessel 27 %
Saphenous graft 2 %
Bifurcation 10 %
Diabetes 18 %
Chronic renal failure 3 %
Left main 2 %
Direct stenting 34 %
“REAL WORLD”
Therefore, we can say that the COMPARE trial truly reflects a real world situation with:……… 13
SOURCE: Smits COMPARE Trial, TCT 2009 13

13. MACE (All death, non-fatal MI, and TVR)
COMPARE: XIENCE V vs. TAXUS Liberté Primary Endpoint (MACE: Death, MI and TVR)
Taxus
XIENCE
31% ↓ in MACE, p= 0.023
P = (log-rank test)
RR = 0.69 ( )
9.1 %
Δ 2.9 %
Δ 1.1%
6.2 %
XIENCE V is superior to TAXUS Liberté in 1,800 real-world, all comer patients
31% reduction in the primary endpoint of MACE (p=.023)
74% reduction in the secondary endpoint of stent thrombosis (p=0.002)
Benefits of XIENCE V over TAXUS translated across platforms with compelling data in SPIRIT IV and COMPARE (TAXUS is TAXUS!)
This is the result of the primary end-point: the combination of all death, non fatal MI and TVR.
At 12 months follow up, a significant higher incidence of MACE occurred in the Taxus stent group compared to the Xience stent group.
The MACE rate is 9.1% in Taxus versus 6.2% in Xience, which is significant different according the log rank test, with a rate ratio of 0.69 and 95% Confidence Interval of
Of interest is the early difference in events between both groups of 1.1% at 30 days, which gradually increased over time to 2.9% at 12 months follow-up .
# Patients at Risk
MACE (All death, non-fatal MI, and TVR)
Taxus
Xience 14
SOURCE: Smits COMPARE Trial, TCT 2009 14

14. COMPARE: XIENCE V vs. TAXUS Liberté Secondary Endpoint (Stent Thrombosis)
74% ↓ in risk of stent thrombosis at 1 year
P = (log-rank test)
RR = 0.26 ( )
2.6 %
NNT (number needed to treat) to prevent 1 ST Event is only 53 Patients
∆ = 1.9%
Definite & probable stent thrombosis rate according to the ARC definitions was also highly significant different between both groups, with a 2.6% in the Taxus group versus 0.7% in the Xience group. This is mainly due to a difference in early stent thrombosis, as shown ……(next dia)
0.7 %
A.R.C. Definite & probable stent thrombosis
SOURCE: Smits COMPARE Trial, TCT 2009 15

15. Xience V versus Taxus Clinical Data: Level of Evidence = A
SPIRIT III – Angiographic superiority over Taxus with efficacy and safety proven long term (3-yrs)
SPIRIT IV – Statistically-significant reduction in TLF and TLR as well as stent thrombosis compared to Taxus, thus showing both improved efficacy and safety, in the largest prospective RCT of DES to date
COMPARE – Outstanding one year safety and efficacy data, again statistically-significant vs. TAXUS Liberte in a real world population 16

16. XIENCE V : The Foundation for Future Products
DRUG/ DOSE
POLYMER/ RELEASE RATE
STENT MATERIAL
STENT DELIVERY SYSTEM (SDS)
STENT DESIGN
PRODUCT
Everolimus
Fluorinated
Copolymer
Cobalt
Chromium
Fluorinated Copolymer
Cobalt Chromium
XIENCE V®
ML VISION
ML VISION
XIENCE PRIME*
NEW
NEW
NEW Ultra-Thin Alloy
Next Gen DES*
NEW
NEW
Bioresorbable*
Polylactic Acid
Polylactic Acid
ML VISION
NEW
*Note: Pipeline products currently in development at Abbott Vascular. Not available for sale. Pictures on file at Abbott Vascular.

17. Ultra-Thin New Alloy % Endothelial Coverage SEM
VISION®
(844 R)
Ultra-Thin NewAlloy
(841 R)
(839R)
839L
above between overall 20 40 60 80
100
p= 0.04
p= 0.35
p= 0.045
7 days
(n=8 each)
UltaThin
Vision
UltraThin
Vision
UltraThin
Vision
above between overall 20 40 60 80
100
p= 0.37
p= 0.85
p= 0.51
11 days
(n=8 each)
UltraThin
Vision
UltraThin
Vision
UltraThin
Vision
Data expressed as a mean±SD
Matched pairs analysis
Pipeline product. Currently in development at Abbott Vascular. Not available for sale.

18. Redesigned Delivery System Based on MULTI-LINK® FRONTIER™ Concept
Side-Branch Access DES Program: XIENCE™ Coating Technology and MULTI-LINK® FRONTIER™ Concept
XIENCE™ V Coating and Materials
Redesigned Delivery System Based on MULTI-LINK® FRONTIER™ Concept
XIENCE™
Coating Technology
Single Tip Delivery
Abbott Side-Branch Access DES
Dual Balloon Inflation
MULTI-LINK VISION®
CoCr Design
In designing a DES for bifurcations, we are building on the proven Frontier platform. This stainless steel stent is uniquely designed to allow for straightforward provisional T stenting and maintaining side branch access throughout the procedure. The stent is delivered over an RX catheter with the two tips joined together. After crossing the main branch lesion, the wire joining the tips is removed and the side branch is wired. The main branch and side branch balloons inflate simultaneously. We are coupling this desing with 6th generation stent technology, based on the Multi Link Vision platform. The new product will be a Cobalt Chromium stent mounted on a modified Vision delivery system and incorporates the Xience V drug formulation coating.
MULTI-LINK® FRONTIER™ Deployment Concept
Flexible MULTI-LINK VISION® Catheter
ML Frontier™ is neither approved nor available in the US.

19. Xience SBA (Side-Branch Access) Stent Full Deployment with Side-Branch Preservation
Porcine Model
On file at Abbott Vascular.

20. The Fourth Revolution Fully Bioresorbable Devices The Abbott Vascular BVS Program
Everolimus-Eluting, Fully Bioresorbable Scaffold
CRT 2010
Pipeline product. Currently in development at Abbott Vascular. Not available for sale.

21. ABSORB: First-in-Man Serial IVUS Results – Per Treatment
Post-PCI
6-month F/U
2-year F/U
% Diff (6M to 2Y)
p-value
n=16
Vessel (EEM) area (mm2)
13.17*
13.11*
12.56*
-4.89
0.055
Lumen area (mm2)
5.99
4.92
5.60
+11.53
0.034
Plaque area (mm2)
7.44*
8.60*
7.10*
-17.44
<0.001
Minimal Lumen area (mm2)
5.05
3.76
4.54
+18.32
0.005
*n=24
*n=15
Serruys, P, et al. Lancet 2009; 373:
P-values per Wilcoxon’s signed rank test
Pipeline product. Currently in development at Abbott Vascular. Not available for sale. 22

22. BVS 3-Year Follow-Up Example of Strut Resorption by OCT
Serruys, ICI 2009
Pipeline product. Currently in development at Abbott Vascular. Not available for sale.

23. A Pipeline That Will Deliver
20 Programs in Development
PROGRAMS IN DEVELOPMENT
PROGRAMS
DES 2.25mm
Next Gen DES
XIENCE SBA
New Alloy DES
DES 4
Coronary Guide Wires 3
Next Generation BMW
PROGRESS1
Next Generation HI-TORQUE® Frontline
HP Versatility
Next Gen Frontline BDC
.014 RX Carotid/Renal BDC
.014 RX BTK BDC
Next Generation .035 BDC
Fox sv (expanded matrix)
Peripheral Drug Coated Balloon
Balloon Dilatation Catheters 7
Bare Metal Stents 2
Next Gen BMS
Ultra-Thin Alloy BMS
Balloon Expandable Stents
Balloon Expandable Peripheral Stent
Renal Stent
Key Messages:
We have a deep product pipeline with 20 programs in development across our Coronary, Endovascular, Carotid, and Vessel Closure businesses
Our pipeline cadence shows our commitment to furthering innovation and development. Continuously improving our technologies for the better treatment of patients. Our DES portfolio includes 4 new programs to improve on the outcomes of XIENCE V® plus a peripheral DES program. Plus new technologies that will change performance (new alloys, bioabsorbable devices)
We are significantly ahead of competitors with our bioabsorbable device program
BSX has been saying we’re a one-trick pony with XIENCE V®, but we are making significant investments across the portfolio
Note: DES 2.25mm is XIENCE Nano
Note: Next Gen DES is XIENCE PRIME
Note: XIENCE SBA is side branch access (internally known as Pathfinder)
Note: New Alloy DES is the ThinMan program 2
Bioresorbable Devices
Bioresorbable Technology (BVS) 1
Self-Expanding Stents 1
Program in Development
1 Pending 510(k) clearance
Note: Pipeline products currently in development at Abbott Vascular. Not available for sale.